Department of Neurosurgery, Severance Hospital, Brain Korea 21 Project for Medical Science, Brain Research Institute, Yonsei University College of Medicine, Seoul, Korea.
Neuromodulation. 2010 Oct;13(4):255-60. doi: 10.1111/j.1525-1403.2009.00273.x.
We compared the role of subthalamic nucleus deep brain stimulation (STN-DBS) in the management of medically refractory idiopathic Parkinson's disease in patients with relatively young onset (<40 years of age) Parkinson's disease (YOPD) and patients with relatively late onset Parkinson's disease (≥ 56 years of age, rLOPD).
A total of 33 patients with YOPD (18 patients, median age 32.5 years, range, 20-40 years) and rLOPD (15 patients, median age 58.0 years, range, 56.0-67.0 years) underwent STN-DBS between May 2000 and May 2008. We divided the patients into YOPD and rLOPD as the age of disease onset. The median follow-up period was 43 months (range, 12-95 months). We assessed Hoehn and Yahr stages, activities of daily living, and Unified Parkinson's Disease Rating Scale (UPDRS) motor scales (III) for all patients preoperatively and at six months postoperatively. We measured levodopa equivalent doses (LEDD) and stimulation parameters preoperatively, six months postoperatively, and 12 months postoperatively.
There were no significant differences in UPDRS motor scales between two groups at preoperative and six-month postoperative drug off/stim on, but UPDRS III was lower in rLOPD at six-month postoperative drug on/stim on state. A significant difference was noted in the improvement of UPDRS III between two groups for preoperative drug off and drug on conditions, but no difference was seen between two groups in a comparison of drug off/stim on vs. drug on/stim on conditions. Stimulation parameters and postoperative LEDD were not different between the two groups. Preoperative dyskinesia was more common in YOPD patients and, psychotic problems were more common in rLOPD patients.
Patients with YOPD and rLOPD exhibited comparable UPDRS motor scores and LEDD six months postoperatively. Levodopa could be prescribed at optimum doses following STN-DBS in patients with YOPD as abnormal movements are better controlled following STN-DBS implantation. Stimulation parameters were not different between the two groups. Our results suggest the age of onset does not influence response to STN-DBS Parkinson's disease patients.
我们比较了丘脑底核深部脑刺激(STN-DBS)在管理年轻起病(<40 岁)特发性帕金森病(YOPD)和老年起病(≥56 岁,rLOPD)帕金森病患者中的作用。
2000 年 5 月至 2008 年 5 月,33 例 YOPD(18 例,中位年龄 32.5 岁,范围 20-40 岁)和 rLOPD(15 例,中位年龄 58.0 岁,范围 56.0-67.0 岁)患者接受了 STN-DBS。我们将患者按发病年龄分为 YOPD 和 rLOPD。中位随访时间为 43 个月(范围 12-95 个月)。我们评估了所有患者术前和术后 6 个月的 Hoehn 和 Yahr 分期、日常生活活动和统一帕金森病评定量表(UPDRS)运动量表(III)。我们测量了术前、术后 6 个月和术后 12 个月的左旋多巴等效剂量(LEDD)和刺激参数。
两组患者术前和术后 6 个月药物关/刺激开时 UPDRS 运动量表无显著差异,但 rLOPD 组术后 6 个月药物开/刺激开时 UPDRS III 较低。两组术前药物关和药物开状态下 UPDRS III 的改善有显著差异,但药物关/刺激开与药物开/刺激开状态下两组之间无差异。两组之间刺激参数和术后 LEDD 无差异。YOPD 患者术前更常见运动障碍,rLOPD 患者更常见精神问题。
YOPD 和 rLOPD 患者术后 6 个月 UPDRS 运动评分和 LEDD 相似。STN-DBS 后可给予 YOPD 患者最佳剂量的左旋多巴,因为 STN-DBS 植入后异常运动得到更好的控制。两组之间的刺激参数没有差异。我们的结果表明,发病年龄不影响 STN-DBS 帕金森病患者的反应。